ArticleBlood2016

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

Harriet S Walter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.